Myocarditis secondary prevention

Myocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Adrenergic Myocarditis
Giant Cell Myocarditis

Causes

Differentiating Myocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myocarditis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Myocarditis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myocarditis secondary prevention

CDC on Myocarditis secondary prevention

Myocarditis secondary prevention in the news

Blogs on Myocarditis secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myocarditis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Homa Najafi, M.D.[2]

## Overview[edit | edit source]

Effective measures for the secondary prevention of myocarditis include, clinical evaluation, ECG, and echocardiography. CMR, cardiac CT scan, nuclear assessment in patients that echocardiography is undiagnostic. Patients should udergo cardiac function assessment at one and six months and yearly after that.

## Secondary Prevention[edit | edit source]

* Effective measures for the secondary prevention of myocarditis include:[1][2]
* Clinical evaluation
* ECG
* Echocardiography
* CMR, cardiac CT scan, nuclear assessment in patients that echocardiography is undiagnostic

* Patients should undergo cardiac function assessment at one and six months and yearly after that.

## References[edit | edit source]

1. ↑ Caforio, A. L. P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S. B.; Fu, M.; Helio, T.; Heymans, S.; Jahns, R.; Klingel, K.; Linhart, A.; Maisch, B.; McKenna, W.; Mogensen, J.; Pinto, Y. M.; Ristic, A.; Schultheiss, H.-P.; Seggewiss, H.; Tavazzi, L.; Thiene, G.; Yilmaz, A.; Charron, P.; Elliott, P. M. (2013). "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases". European Heart Journal. 34 (33): 2636–2648. doi:10.1093/eurheartj/eht210. ISSN 0195-668X.
2. ↑ C. L. Miklozek, E. M. Kingsley, C. S. Crumpaker, J. F. Modlin, H. D. Royal, P. C. Come, R. Mark & W. H. Abelmann (1986). "Serial cardiac function tests in myocarditis". Postgraduate medical journal. 62 (728): 577–579. doi:10.1136/pgmj.62.728.577. PMID 3774697. Unknown parameter `|month=` ignored (help)CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS